RBC Capital on Edgewise Therapeutics (EWTX): 'We See Downside Move As A Buying Opportunity'; PT Lowered
Tweet Send to a Friend
RBC Capital analyst Leonid Timashev lowered the price target on Edgewise Therapeutics (NASDAQ: EWTX) to $52.00 (from $56.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
